$4.27
0.70% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US74754R1032
Symbol
QLGN
Sector
Industry

Qualigen Therapeutics Inc Stock price

$4.27
-0.39 8.37% 1M
-4.64 52.05% 6M
-23.23 84.47% YTD
-23.71 84.74% 1Y
-605.73 99.30% 3Y
-1,933.23 99.78% 5Y
-619,995.73 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 0.70%
ISIN
US74754R1032
Symbol
QLGN
Sector
Industry

Key metrics

Market capitalization $3.14m
Enterprise Value $4.18m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-6.70m
Cash position $390.00k
EPS (TTM) EPS $-55.30
P/E forward negative
Short interest 2.85%
Show more

Is Qualigen Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Qualigen Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Qualigen Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Qualigen Therapeutics Inc:

Buy
100%

Financial data from Qualigen Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.13 4.13
52% 52%
-
- Research and Development Expense 2.55 2.55
62% 62%
-
-6.69 -6.69
53% 53%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.70 -6.70
54% 54%
-
Net Profit -7.77 -7.77
54% 54%
-

In millions USD.

Don't miss a Thing! We will send you all news about Qualigen Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Qualigen Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” o...
Neutral
GlobeNewsWire
about 2 months ago
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when t...
Neutral
GlobeNewsWire
3 months ago
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financ...
More Qualigen Therapeutics Inc News

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.

Head office United States
CEO Kevin Richardson
Employees 4
Founded 2004
Website qlgntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today